Immunovant Inc reports results for the quarter ended in June - Earnings Summary

Immunovant

08/08/2024 13:21

* Immunovant Inc  IMVT.OQ  reported a quarterly adjusted
loss
of 60 cents​​ per share for the quarter ended in June, lower
than the same quarter last year, when the company reported EPS
of -57 cents.  The mean expectation of eleven analysts for the
quarter was for a loss of 53 cents per share. Wall Street
expected results to range from -58 cents to -46 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Immunovant Inc's reported EPS for the quarter was a loss
of 60
cents​.
    * The company reported a quarterly loss of $87.07 million.
    * Immunovant Inc shares had risen by 2.2% this quarter and
lost 36.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 17.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 15 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunovant Inc is
$49.00 
This summary was machine generated from LSEG data August 8 at
12:21 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.53          -0.60          Missed
 Mar. 31 2024      -0.43          -0.52          Missed
 Dec. 31 2023      -0.47          -0.36          Beat
 Sep. 30 2023      -0.47          -0.45          Beat